sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.18699/SSMJ20230203sibmed-1037Research ArticleОБЗОРЫREVIEWSЭритропоэтин: функции и терапевтический потенциалErythropoietin: function and therapeutic potentialhttps://orcid.org/0000-0003-4897-8676ЛыковА. П.LykovA. P.

 Лыков Александр Петрович, к.м.н.

630040, г. Новосибирск, ул. Охотская, 81а

  Alexander P. Lykov, candidate of medical sciences 

630040, Novosibirsk, Okhotskaya str., 81a 

aplykov2@mail.ruНовосибирский НИИ туберкулеза Минздрава РоссииРоссияNovosibirsk Research Institute of Tuberculosis of Minzdrav of RussiaRussian Federation2023270420234322939Copyright © Лыков А.П., 20232023Лыков А.П.Lykov A.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/1037

Эритропоэтин (ЭПО) проявляет свое действие на клетки эритроидного ростка через взаимодействие с рецептором к ЭПО (ЭПОР), так называемый канонический путь, и через комплекс, состоящий из ЭПОР и общей субъединицы бета-рецептора цитокинов (CD131) – неканонический путь для негемопоэтических клеток организма человека и животных. Эффект ЭПО реализуется через запуск каскада сигналинга, который начинается с фосфорилирования янус-киназы 2 (JAK2) и далее с вовлечением фосфатидилинозит-3 киназы В (PI3K) или Rasмитоген-активируемой протеинкиназы (MAPK) или сигнальных преобразователей и активаторов транскрипции (STAT). ЭПО оказывает прямое цитопротективное действие через усиление экспрессии CD131 с последующим антиапоптотическим и противовоспалительным эффектом в клетках-мишенях. Помимо использования в лечении анемий, ЭПО находит все большее применение при коррекции воспалительно-дегенеративных процессов как в экспериментальных, так и в клинических клеточно-опосредованных исследованиях. ЭПО способствует приживлению стволовых клеток, дифференцировке мезенхимных стволовых клеток в соединительнотканном направлении, подавляет воспалительный ответ и апоптоз клеток в очаге поражения. В статью включены данные литературы, касающиеся ЭПО и его клинического использования при воспалительно-дегенеративных процессах, на основе данных eLibrary и Национального центра биотехнологической информации (NCBI) за период с 1998 по 2022 г.

Erythropoietin (EPO) exerts its effect on erythroid lineage cells through interaction with the EPO receptor (EPOR), the so-called canonical pathway, and through a complex consisting of EPOR and a common cytokine receptor beta subunit (CD131) – a non-canonical pathway for non-hematopoietic cells of the human and animal body. EPO realizes its effects through the launch of a signaling cascade, which begins with the phosphorylation of Janus kinase 2 (JAK2) and then with the involvement of phosphatidylinositol-3 kinase B (PI3K) or Ras-mitogen-activated protein kinase (MAPK) or signal transducers and transcription activators (STAT). EPO exhibits a direct cytoprotective effect through increased CD131 expression and subsequent development of anti-apoptotic and anti-inflammatory effects in target cells. In addition to its use in the treatment of anemia, EPO is increasingly being used in correction of inflammatory and degenerative processes, both in experimental and clinical studies. EPO promotes the engraftment of stem cells, differentiation of mesenchymal stem cells in the connective tissue direction, suppresses the inflammatory response and apoptosis of cells in the lesion. The article includes literature data concerning EPO and its clinical use in inflammatory and degenerative processes, based on data from eLibrary and the National Center for Biotechnological Information (NCBI) for the period 1998–2022.

эритропоэтинрецептор к эритропоэтинуцитопротективное действиеантиапоптотическое действиепротивовоспалительное действиетерапевтический потенциал.erythropoietinerythropoietin receptorcytoprotective effectanti-apoptotic and anti-inflammatory effectstherapeutic potential.ReferencesJelkmann W. Molecular biology of erythropoietin. Intern. Med. 2004;43(8):649–659. doi:10.2169/internalmedicine.43.649Jelkmann W. Molecular biology of erythropoietin. Intern. Med. 2004;43(8):649–659. doi:10.2169/internalmedicine.43.649Ratcliffe P.J. HIF-1 and HIF-2: working alone or together in hypoxia? J. Clin. Invest. 2007;117(4):862–865. doi:10.1172/JCI31750Ratcliffe P.J. HIF-1 and HIF-2: working alone or together in hypoxia? J. Clin. Invest. 2007;117(4):862–865. doi:10.1172/JCI31750Percy M.J., Beer P.A., Campbell G., Dekker A.W., Green A.R., Oscier D., Rainey M.G., van Wijk R., Wood M., Lappin T.R., McMullin M.F., Lee F.S. Novel exon 12 mutations in the HIF2A gene associatedwith erythrocytosis. Blood. 2008;111(11):5400–5402. doi:10.1182/blood-2008-02-137703Percy M.J., Beer P.A., Campbell G., Dekker A.W., Green A.R., Oscier D., Rainey M.G., van Wijk R., Wood M., Lappin T.R., McMullin M.F., Lee F.S. Novel exon 12 mutations in the HIF2A gene associatedwith erythrocytosis. Blood. 2008;111(11):5400–5402. doi:10.1182/blood-2008-02-137703Cantarelli C., Angeletti A., Cravedi P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am. J. Transplant. 2019;19(9):2407–2414. doi: 10.1111/ajt.15369Cantarelli C., Angeletti A., Cravedi P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am. J. Transplant. 2019;19(9):2407–2414. doi: 10.1111/ajt.15369Ma Y., Zhou Z., Yang G.Y., Ding J., Wang X. The effect of erythropoietin and its derivatives on ischemic stroke therapy: a comprehensive review. Front. Pharmacol. 2022;13:743926. doi: 10.3389/fphar.2022.743926Ma Y., Zhou Z., Yang G.Y., Ding J., Wang X. The effect of erythropoietin and its derivatives on ischemic stroke therapy: a comprehensive review. Front. Pharmacol. 2022;13:743926. doi: 10.3389/fphar.2022.743926Neubauer H., Cumano A., Müller M., Wu H., Huffstadt U., Pfeffer K. Jak2 defciency defnes an essential developmental checkpoint in defnitive hematopoiesis. Cell. 1998;93(3):397–409. doi:10.1016/s0092-8674(00)81168-xNeubauer H., Cumano A., Müller M., Wu H., Huffstadt U., Pfeffer K. Jak2 defciency defnes an essential developmental checkpoint in defnitive hematopoiesis. Cell. 1998;93(3):397–409. doi:10.1016/s0092-8674(00)81168-xTefferi A., Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratifcation and management. Am. J. Hematol. 2020;95(12):1599–1613. doi:10.1002/ajh.26008Tefferi A., Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratifcation and management. Am. J. Hematol. 2020;95(12):1599–1613. doi:10.1002/ajh.26008Jelkmann W. Erythropoietin. Front. Horm. Res. 2016;47:115–127. doi: 10.1159/000445174Jelkmann W. Erythropoietin. Front. Horm. Res. 2016;47:115–127. doi: 10.1159/000445174Kimáková P., Solár P., Solárová Z., Komel R., Debeljak N. Erythropoietin and its angiogenic activity. Int. J. Mol. Sci. 2017;18(7):1519. doi: 10.3390/ijms18071519Kimáková P., Solár P., Solárová Z., Komel R., Debeljak N. Erythropoietin and its angiogenic activity. Int. J. Mol. Sci. 2017;18(7):1519. doi: 10.3390/ijms18071519Uversky V.N., Redwan E.M. Erythropoietin and co.: intrinsic structure and functional disorder. Mol. Biosyst. 2016;13(1):56–72. doi: 10.1039/c6mb00657dUversky V.N., Redwan E.M. Erythropoietin and co.: intrinsic structure and functional disorder. Mol. Biosyst. 2016;13(1):56–72. doi: 10.1039/c6mb00657dSchiappacasse A., Maltaneri R.E., Chamorro M.E., Nesse A.B., Wetzler D.E., Vittori D.C. Modifcation of erythropoietin structure by N-homocysteinylation affects its antiapoptotic and proliferative functions. FEBS J. 2018;285(20):3801–3814. doi:10.1111/febs.14632Schiappacasse A., Maltaneri R.E., Chamorro M.E., Nesse A.B., Wetzler D.E., Vittori D.C. Modifcation of erythropoietin structure by N-homocysteinylation affects its antiapoptotic and proliferative functions. FEBS J. 2018;285(20):3801–3814. doi:10.1111/febs.14632Chen Y., Xiang J., Qian F., Diwakar B.T., Ruan B., Hao S., Prabhu K.S., Paulson R.F. Epo receptor signaling in macrophages alters the splenic niche to promote erythroid differentiation. Blood. 2020;136(2):235–246. doi: 10.1182/blood.2019003480Chen Y., Xiang J., Qian F., Diwakar B.T., Ruan B., Hao S., Prabhu K.S., Paulson R.F. Epo receptor signaling in macrophages alters the splenic niche to promote erythroid differentiation. Blood. 2020;136(2):235–246. doi: 10.1182/blood.2019003480Zafriou M.P., Noack C., Unsöld B., Didie M., Pavlova E., Fischer H.J., Reichardt H.M., Bergmann M.W., El-Armouche A., Zimmermann W.H., Zelarayan L.C. Erythropoietin responsive cardiomyogenic cells contribute to heart repair post myocardial infarction. Stem Cells. 2014;32(9):2480–2491. doi:10.1002/stem.1741Zafriou M.P., Noack C., Unsöld B., Didie M., Pavlova E., Fischer H.J., Reichardt H.M., Bergmann M.W., El-Armouche A., Zimmermann W.H., Zelarayan L.C. Erythropoietin responsive cardiomyogenic cells contribute to heart repair post myocardial infarction. Stem Cells. 2014;32(9):2480–2491. doi:10.1002/stem.1741Bohr S., Patel S.J., Vasko R., Shen K., IrachetaVellve A., Lee J., Bale S.S., Chakraborty N., Brines M., Cerami A., Berthiaume F., Yarmush M.L. Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. J. Mol. Med. (Berl.). 2015;93(2):199–210. doi: 10.1007/s00109-014-1218-2Bohr S., Patel S.J., Vasko R., Shen K., IrachetaVellve A., Lee J., Bale S.S., Chakraborty N., Brines M., Cerami A., Berthiaume F., Yarmush M.L. Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. J. Mol. Med. (Berl.). 2015;93(2):199–210. doi: 10.1007/s00109-014-1218-2Lin H., Ling Y., Pan J., Gong H. Therapeutic effects of erythropoietin expressed in mesenchymal stem cells for dilated cardiomyopathy in rat. Biochem. Biophys. Res. Commun. 2019;517(4):575–580. doi: 10.1016/j.bbrc.2019.07.053Lin H., Ling Y., Pan J., Gong H. Therapeutic effects of erythropoietin expressed in mesenchymal stem cells for dilated cardiomyopathy in rat. Biochem. Biophys. Res. Commun. 2019;517(4):575–580. doi: 10.1016/j.bbrc.2019.07.053Kittur F.S., Lin Y., Arthur E., Hung C.Y., Li P.A., Sane D.C., Xie J. Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation. Biochem. Biophys. Rep. 2019;17:157–168. doi: 10.1016/j.bbrep.2019.01.004Kittur F.S., Lin Y., Arthur E., Hung C.Y., Li P.A., Sane D.C., Xie J. Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation. Biochem. Biophys. Rep. 2019;17:157–168. doi: 10.1016/j.bbrep.2019.01.004Wu S.H., Lu I.C., Lee S.S., Kwan A.L., Chai C.Y., Huang S.H. Erythropoietin attenuates motor neuron programmed cell death in a burn animal model. PLoS One. 2018;13(1):e0190039. doi: 10.1371/journal.pone.0190039Wu S.H., Lu I.C., Lee S.S., Kwan A.L., Chai C.Y., Huang S.H. Erythropoietin attenuates motor neuron programmed cell death in a burn animal model. PLoS One. 2018;13(1):e0190039. doi: 10.1371/journal.pone.0190039Eggold J.T., Rankin E.B. Erythropoiesis, EPO, macrophages, and bone. Bone. 2019;119:36–41. doi:10.1016/j.bone.2018.03.014Eggold J.T., Rankin E.B. Erythropoiesis, EPO, macrophages, and bone. Bone. 2019;119:36–41. doi:10.1016/j.bone.2018.03.014Perron-Deshaies G., St-Louis P., Romero H., Scorza T. Impact of erythropoietin production by erythroblastic island macrophages on homeostatic murine erythropoiesis. Int. J. Mol. Sci. 2020;21(23):8930. doi:10.3390/ijms21238930Perron-Deshaies G., St-Louis P., Romero H., Scorza T. Impact of erythropoietin production by erythroblastic island macrophages on homeostatic murine erythropoiesis. Int. J. Mol. Sci. 2020;21(23):8930. doi:10.3390/ijms21238930Melashchenko O.V., Meniailo M.E., Malashchenko V.V., Gazatova N.D., Goncharov A.G., Seledtsova G.V., Seledtsov V.I. Erythropoietin directly affects human macrophage functionality. Curr. Pharm. Biotechnol. 2018;19(11):902–909. doi: 10.2174/1389201019666181031164520Melashchenko O.V., Meniailo M.E., Malashchenko V.V., Gazatova N.D., Goncharov A.G., Seledtsova G.V., Seledtsov V.I. Erythropoietin directly affects human macrophage functionality. Curr. Pharm. Biotechnol. 2018;19(11):902–909. doi: 10.2174/1389201019666181031164520Lisowska K.A., Dębska-Ślizień A., Jasiulewicz A., Daca A., Bryl E., Witkowski M. The influence of recombinant human erythropoietin on apoptosis and cytokine production of CD4+ lymphocytes from hemodialyzed patients. J. Clin. Immunol. 2013;33(3):661–665. doi: 10.1007/s10875-012-9835-4Lisowska K.A., Dębska-Ślizień A., Jasiulewicz A., Daca A., Bryl E., Witkowski M. The influence of recombinant human erythropoietin on apoptosis and cytokine production of CD4+ lymphocytes from hemodialyzed patients. J. Clin. Immunol. 2013;33(3):661–665. doi: 10.1007/s10875-012-9835-4Donadei C., Angeletti A., Cantarelli C., D’Agati V.D., la Manna G., Fiaccadori E., Horwitz J.K., Xiong H., Guglielmo C., Hartzell S., …Cravedi P. Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI Insight. 2019;5(10):e127428. doi: 10.1172/jci.insight.127428Donadei C., Angeletti A., Cantarelli C., D’Agati V.D., la Manna G., Fiaccadori E., Horwitz J.K., Xiong H., Guglielmo C., Hartzell S., …Cravedi P. Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI Insight. 2019;5(10):e127428. doi: 10.1172/jci.insight.127428Purroy C., Fairchild R.L., Tanaka T., Baldwin W.M. 3rd, Manrique J., Madsen J.C., Colvin R.B., Alessandrini A., Blazar B.R., Fribourg M., …Cravedi P. Erythropoietin receptor-mediated molecular crosstalk promotes T cell immunoregulation and transplant survival. J. Am. Soc. Nephrol. 2017;28(8):2377–2392. doi: 10.1681/ASN.2016101100Purroy C., Fairchild R.L., Tanaka T., Baldwin W.M. 3rd, Manrique J., Madsen J.C., Colvin R.B., Alessandrini A., Blazar B.R., Fribourg M., …Cravedi P. Erythropoietin receptor-mediated molecular crosstalk promotes T cell immunoregulation and transplant survival. J. Am. Soc. Nephrol. 2017;28(8):2377–2392. doi: 10.1681/ASN.2016101100Deshet-Unger N., Kolomansky A., Ben-Califa N., Hiram-Bab S., Gilboa D., Liron T., Ibrahim M., Awida Z., Gorodov A., Oster H.S., … Neumann D. Erythropoietin receptor in B cells plays a role in bone remodeling in mice. Theranostics. 2020;10(19):8744–8756. doi: 10.7150/thno.45845Deshet-Unger N., Kolomansky A., Ben-Califa N., Hiram-Bab S., Gilboa D., Liron T., Ibrahim M., Awida Z., Gorodov A., Oster H.S., … Neumann D. Erythropoietin receptor in B cells plays a role in bone remodeling in mice. Theranostics. 2020;10(19):8744–8756. doi: 10.7150/thno.45845Peng B., Kong G., Yang C., Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020;11(2):79. doi: 10.1038/s41419-020-2276-8Peng B., Kong G., Yang C., Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020;11(2):79. doi: 10.1038/s41419-020-2276-8Kang J., Yun J.Y., Hur J., Kang J.A., Choi J.I., Ko S.B., Lee J., Kim J.Y., Hwang I.C., Park Y., Kim H.S. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. Cardiovasc. Res. 2014;104(1):171–182. doi: 10.1093/cvr/cvu180Kang J., Yun J.Y., Hur J., Kang J.A., Choi J.I., Ko S.B., Lee J., Kim J.Y., Hwang I.C., Park Y., Kim H.S. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. Cardiovasc. Res. 2014;104(1):171–182. doi: 10.1093/cvr/cvu180Лыков А.П., Суровцева М.А., Повещенко О.В., Чернявский А.М., Фомичев А.В., Бондаренко Н.А., Ким И.И. Влияние эритропоэтина на костномозговые мононуклеары. Мед. иммунол. 2020;22(1):135–142. doi: 10.15789/1563-0625-EEO-1807Lykov A.P., Surovtseva M.A., Poveshchenko O.V., Chernyavsky A.M., Fomichev A.V., Bondarenko N.A., Kim I.I. Effect of erythropoietin on bonemarrow mononuclear cells. Meditsinskaya immunologiya = Medical Immunology. 2020;22(1):135–142. [In Russian]. doi:10.15789/1563-0625-EEO-1807Лыков А.П., Суровцева М.А., Повещенко О.В., Бондаренко Н.А., Ким И.И., Чернявский А.М., Фомичев А.В. Влияние эритропоэтина на продукцию цитокинов стволовыми клетками. Мед. иммунол. 2019;21(5):861–868. doi: 10.15789/1563-0625-2019-5-861-868Lykov A.P., Surovtseva M.A., Poveshchenko O.V., Bondarenko N.A., Kim I.I., Chernyavsky A.M., Fomichev A.V. Effect of erythropoietin on cytokine production by stem cells. Meditsinskaya immunologiya = Medical Immunology. 2019;21(5):861–868. [In Russian]. doi: 10.15789/1563-0625-2019-5-861-868Rölfng J.H., Baatrup A., Stiehler M., Jensen J., Lysdahl H., Bünger C. The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dosedependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways. Stem. Cell Rev. Rep. 2014;10(1):69–78. doi: 10.1007/s12015-013-9476-xRölfng J.H., Baatrup A., Stiehler M., Jensen J., Lysdahl H., Bünger C. The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dosedependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways. Stem. Cell Rev. Rep. 2014;10(1):69–78. doi: 10.1007/s12015-013-9476-xChang J.R., Sun N., Liu Y., Wei M., Zhao Y., Gan L., Zhu J.X., Su X.L. Erythropoietin attenuates vascular calcifcation by inhibiting endoplasmic reticulum stress in rats with chronic kidney disease. Peptides. 2020;123:170181. doi: 10.1016/j.peptides.2019.170181Chang J.R., Sun N., Liu Y., Wei M., Zhao Y., Gan L., Zhu J.X., Su X.L. Erythropoietin attenuates vascular calcifcation by inhibiting endoplasmic reticulum stress in rats with chronic kidney disease. Peptides. 2020;123:170181. doi: 10.1016/j.peptides.2019.170181Lykov A.P., Surovtseva M.A., Kim I.I., Bondarenko N.A., Poveshchenko O.V. Effect of erythropoietin on morphofunctional properties of mesenchymal stem cells. Bull. Exp. Biol. Med. 2020;170(1):164–170. doi: 10.1007/s10517-020-05024-zLykov A.P., Surovtseva M.A., Kim I.I., Bondarenko N.A., Poveshchenko O.V. Effect of erythropoietin on morphofunctional properties of mesenchymal stem cells. Bull. Exp. Biol. Med. 2020;170(1):164–170. doi: 10.1007/s10517-020-05024-zWang L., Wu F., Song Y., Duan Y., Jin Z. Erythropoietin induces the osteogenesis of periodontal mesenchymal stem cells from healthy and periodontitis sources via activation of the p38 MAPK pathway. Int. J. Mol. Med. 2018;41(2):829–835. doi: 10.3892/ijmm.2017.3294Wang L., Wu F., Song Y., Duan Y., Jin Z. Erythropoietin induces the osteogenesis of periodontal mesenchymal stem cells from healthy and periodontitis sources via activation of the p38 MAPK pathway. Int. J. Mol. Med. 2018;41(2):829–835. doi: 10.3892/ijmm.2017.3294Zhou J., Wei F., Ma Y. Inhibiting PPARγ by erythropoietin while upregulating TAZ by IGF1 synergistically promote osteogenic differentiation of mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2016;478(1):349–355. doi: 10.1016/j.bbrc.2016.07.049Zhou J., Wei F., Ma Y. Inhibiting PPARγ by erythropoietin while upregulating TAZ by IGF1 synergistically promote osteogenic differentiation of mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2016;478(1):349–355. doi: 10.1016/j.bbrc.2016.07.049Tari K., Atashi A., Kaviani S., AkhavanRahnama M., Anbarlou A., Mossahebi-Mohammadi M. Erythropoietin induces production of hepatocyte growth factor from bone marrow mesenchymal stem cells in vitro. Biologicals. 2017;45:15–19. doi: 10.1016/j.biologicals.2016.10.010Tari K., Atashi A., Kaviani S., AkhavanRahnama M., Anbarlou A., Mossahebi-Mohammadi M. Erythropoietin induces production of hepatocyte growth factor from bone marrow mesenchymal stem cells in vitro. Biologicals. 2017;45:15–19. doi: 10.1016/j.biologicals.2016.10.010Cui J., Liu X., Zhang Z., Xuan Y., Liu X., Zhang F. EPO protects mesenchymal stem cells from hyperglycaemic injury via activation of the Akt/FoxO3a pathway. Life Sci. 2019;222:158–167. doi: 10.1016/j.lfs.2018.12.045Cui J., Liu X., Zhang Z., Xuan Y., Liu X., Zhang F. EPO protects mesenchymal stem cells from hyperglycaemic injury via activation of the Akt/FoxO3a pathway. Life Sci. 2019;222:158–167. doi: 10.1016/j.lfs.2018.12.045Hu M.C., Shi M., Cho H.J., Zhang J., Pavlenco A., Liu S., Sidhu S., Huang L.J., Moe O.W. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int. 2013;84(3):468–481. doi: 10.1038/ki.2013.149Hu M.C., Shi M., Cho H.J., Zhang J., Pavlenco A., Liu S., Sidhu S., Huang L.J., Moe O.W. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int. 2013;84(3):468–481. doi: 10.1038/ki.2013.149Tsai T.H., Lu C.H., Wallace C.G., Chang W.N., Chen S.F., Huang C., Tsai N.W., Lan M.Y., Sung P.H., Liu C.F., Yip H.K. Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial. Crit. Care. 2015;19(1):49. doi: 10.1186/s13054-015-0761-8Tsai T.H., Lu C.H., Wallace C.G., Chang W.N., Chen S.F., Huang C., Tsai N.W., Lan M.Y., Sung P.H., Liu C.F., Yip H.K. Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial. Crit. Care. 2015;19(1):49. doi: 10.1186/s13054-015-0761-8Garrigue P., Hache G., Bennis Y., Brige P., Stalin J., Pellegrini L., Velly L., Orlandi F., Castaldi E., Dignat-George F., Sabatier F., Guillet B. Erythropoietin pretreatment of transplanted endothelial colony-forming cells enhances recovery in a cerebral ischemia model by increasing their homing ability: a SPECT/CT study. J. Nucl. Med. 2016;57(11):1798–1804. doi:10.2967/jnumed.115.170308Garrigue P., Hache G., Bennis Y., Brige P., Stalin J., Pellegrini L., Velly L., Orlandi F., Castaldi E., Dignat-George F., Sabatier F., Guillet B. Erythropoietin pretreatment of transplanted endothelial colony-forming cells enhances recovery in a cerebral ischemia model by increasing their homing ability: a SPECT/CT study. J. Nucl. Med. 2016;57(11):1798–1804. doi:10.2967/jnumed.115.170308Zhang S., Shi B. Erythropoietin modifcation enhances the protection of mesenchymal stem cells on diabetic rat-derived schwann cells: implications for diabetic neuropathy. Biomed. Res. Int. 2017;2017:6352858. doi: 10.1155/2017/6352858Zhang S., Shi B. Erythropoietin modifcation enhances the protection of mesenchymal stem cells on diabetic rat-derived schwann cells: implications for diabetic neuropathy. Biomed. Res. Int. 2017;2017:6352858. doi: 10.1155/2017/6352858Li J., Guo W., Xiong M., Zhang S., Han H., Chen J., Mao D., Yu H., Zeng Y. Erythropoietin facilitates the recruitment of bone marrow mesenchymal stem cells to sites of spinal cord injury. Exp. Ther. Med. 2017;13(5):1806–1812. doi: 10.3892/etm.2017.4182Li J., Guo W., Xiong M., Zhang S., Han H., Chen J., Mao D., Yu H., Zeng Y. Erythropoietin facilitates the recruitment of bone marrow mesenchymal stem cells to sites of spinal cord injury. Exp. Ther. Med. 2017;13(5):1806–1812. doi: 10.3892/etm.2017.4182Zhang H., Fang X., Huang D., Luo Q., Zheng M., Wang K., Cao L., Yin Z. Erythropoietin signaling increases neurogenesis and oligodendrogenesis of endogenous neural stem cells following spinal cord injury both in vivo and in vitro. Mol. Med. Rep. 2018;17(1):264–272. doi: 10.3892/mmr.2017.7873Zhang H., Fang X., Huang D., Luo Q., Zheng M., Wang K., Cao L., Yin Z. Erythropoietin signaling increases neurogenesis and oligodendrogenesis of endogenous neural stem cells following spinal cord injury both in vivo and in vitro. Mol. Med. Rep. 2018;17(1):264–272. doi: 10.3892/mmr.2017.7873Si W., Wang J., Li M., Qu H., Gu R., Liu R., Wang L., Li S., Hu X. Erythropoietin protects neurons from apoptosis via activating PI3K/AKT and inhibiting Erk1/2 signaling pathway. 3 Biotech. 2019;9(4):131. doi: 10.1007/s13205-019-1667-ySi W., Wang J., Li M., Qu H., Gu R., Liu R., Wang L., Li S., Hu X. Erythropoietin protects neurons from apoptosis via activating PI3K/AKT and inhibiting Erk1/2 signaling pathway. 3 Biotech. 2019;9(4):131. doi: 10.1007/s13205-019-1667-yChen S.J., Wang Y.L., Lo W.T., Wu C.C., Hsieh C.W., Huang,C.F., Lan Y.H., Wang C.C., Chang D.M., Sytwu H.K. Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2010; 162(2):210–223. doi: 10.1111/j.1365-2249.2010.04238.xChen S.J., Wang Y.L., Lo W.T., Wu C.C., Hsieh C.W., Huang,C.F., Lan Y.H., Wang C.C., Chang D.M., Sytwu H.K. Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2010; 162(2):210–223. doi: 10.1111/j.1365-2249.2010.04238.xZhong L., Zhang H., Ding Z.F., Li J., Lv J.W., Pan Z.J., Xu D.X., Yin Z.S. Erythropoietin-induced autophagy protects against spinal cord injury and improves neurological function via the extracellular-regulated protein kinase signaling pathway. Mol. Neurobiol. 2020;57(10):3993–4006. doi: 10.1007/s12035-020-01997-0Zhong L., Zhang H., Ding Z.F., Li J., Lv J.W., Pan Z.J., Xu D.X., Yin Z.S. Erythropoietin-induced autophagy protects against spinal cord injury and improves neurological function via the extracellular-regulated protein kinase signaling pathway. Mol. Neurobiol. 2020;57(10):3993–4006. doi: 10.1007/s12035-020-01997-0Huang R., Zhang J., Ren C., Zhang X., Gu L., Dong Y., Zhang J., Zhang J. Effect of erythropoietin on Fas/FasL expression in brain tissues of neonatal rats with hypoxic-ischemic brain damage. Neuroreport. 2019;30(4):262–268. doi: 10.1097/WNR.0000000000001194Huang R., Zhang J., Ren C., Zhang X., Gu L., Dong Y., Zhang J., Zhang J. Effect of erythropoietin on Fas/FasL expression in brain tissues of neonatal rats with hypoxic-ischemic brain damage. Neuroreport. 2019;30(4):262–268. doi: 10.1097/WNR.0000000000001194Jasiulewicz A., Lisowska K.A., Dębska-Ślizień A., Witkowski J.M. Phenotype, proliferation and apoptosis of B lymphocytes in hemodialysis patients treated with recombinant human erythropoietin. Int. Immunol. 2016;28(11):523–532. doi: 10.1093/intimm/dxw032Jasiulewicz A., Lisowska K.A., Dębska-Ślizień A., Witkowski J.M. Phenotype, proliferation and apoptosis of B lymphocytes in hemodialysis patients treated with recombinant human erythropoietin. Int. Immunol. 2016;28(11):523–532. doi: 10.1093/intimm/dxw032Cakiroglu F., Enders-Comberg S.M., Pagel H., Rohwedel J., Lehnert H., Kramer J. Erythropoietin-enhanced endothelial progenitor cell recruitment in peripheral blood and renal vessels during experimental acute kidney injury in rats. Cell. Biol. Int. 2016;40(3):298–307. doi: 10.1002/cbin.10566Cakiroglu F., Enders-Comberg S.M., Pagel H., Rohwedel J., Lehnert H., Kramer J. Erythropoietin-enhanced endothelial progenitor cell recruitment in peripheral blood and renal vessels during experimental acute kidney injury in rats. Cell. Biol. Int. 2016;40(3):298–307. doi: 10.1002/cbin.10566Li J.P., Wang D.W., Song Q.H. Transplantation of erythropoietin gene-transfected umbilical cord mesenchymal stem cells as a treatment for limb ischemia in rats. Genet. Mol. Res. 2015;14(4):19005–19015. doi:10.4238/2015.December.29.8Li J.P., Wang D.W., Song Q.H. Transplantation of erythropoietin gene-transfected umbilical cord mesenchymal stem cells as a treatment for limb ischemia in rats. Genet. Mol. Res. 2015;14(4):19005–19015. doi:10.4238/2015.December.29.8Lykov A.P., Bondarenko N.A., Poveshchenko O.V., Kabakov A.V., Surovtseva M.A., Kim I.I., Kazakov O.V., Poveshchenko A.F., Yankaite E.V. Therapeutic potential of a biomedical cellular product in rats with lower limb ischaemia. Angiol. Sosud. Khir. 2020;26(3):37–43. doi: 10.33529/ANGIO2020315Lykov A.P., Bondarenko N.A., Poveshchenko O.V., Kabakov A.V., Surovtseva M.A., Kim I.I., Kazakov O.V., Poveshchenko A.F., Yankaite E.V. Therapeutic potential of a biomedical cellular product in rats with lower limb ischaemia. Angiol. Sosud. Khir. 2020;26(3):37–43. doi: 10.33529/ANGIO2020315Hu R., Cheng Y., Jing H., Wu H. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. Shock. 2014;42(4):327–336. doi:10.1097/SHK.0000000000000216Hu R., Cheng Y., Jing H., Wu H. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. Shock. 2014;42(4):327–336. doi:10.1097/SHK.0000000000000216Zhang Z., Sun C.., Wang J., Jiang W., Xin Q., Luan Y. Timing of erythropoietin modifed mesenchymal stromal cell transplantation for the treatment of experimental bronchopulmonary dysplasia. J. Cell Mol. Med. 2018;22(11):5759–5763. doi: 10.1111/jcmm.13843Zhang Z., Sun C.., Wang J., Jiang W., Xin Q., Luan Y. Timing of erythropoietin modifed mesenchymal stromal cell transplantation for the treatment of experimental bronchopulmonary dysplasia. J. Cell Mol. Med. 2018;22(11):5759–5763. doi: 10.1111/jcmm.13843Luan Y., Zhang L., Chao S., Liu X., Li K., Wang Y., Zhang Z. Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGF-β1 signaling. Oncotarget. 2016;7(30):47082–47094. doi: 10.18632/oncotarget.9314Luan Y., Zhang L., Chao S., Liu X., Li K., Wang Y., Zhang Z. Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGF-β1 signaling. Oncotarget. 2016;7(30):47082–47094. doi: 10.18632/oncotarget.9314Imam R.A., Rizk A.A. Efcacy of erythropoietin-pretreated mesenchymal stem cells in murine burn wound healing: possible in vivo transdifferentiation into keratinocytes. Folia Morphol. (Warsz). 2019;78(4):798–808. doi: 10.5603/FM.a2019.0038Imam R.A., Rizk A.A. Efcacy of erythropoietin-pretreated mesenchymal stem cells in murine burn wound healing: possible in vivo transdifferentiation into keratinocytes. Folia Morphol. (Warsz). 2019;78(4):798–808. doi: 10.5603/FM.a2019.0038Lykov A.P., Bondarenko N.A., Poveshchenko O.V., Kim I.I., Surovtseva M.A., Sadykova J.B., Semin P.A., Zavjalov E.L., Krivoshapkin A.L., Konenkov V.I. Treatment of intervertebral disc degeneration in Wistar rats with mesenchymal stem cells. Bull. Exp. Biol. Med. 2020;168(4):578–582. doi: 10.1007/s10517-020-04756-2Lykov A.P., Bondarenko N.A., Poveshchenko O.V., Kim I.I., Surovtseva M.A., Sadykova J.B., Semin P.A., Zavjalov E.L., Krivoshapkin A.L., Konenkov V.I. Treatment of intervertebral disc degeneration in Wistar rats with mesenchymal stem cells. Bull. Exp. Biol. Med. 2020;168(4):578–582. doi: 10.1007/s10517-020-04756-2Фомичев А.В., Чернявский А.М., Гуляева К.К., Повещенко О.В., Лыков А.П., Карева Ю.Е., Минин С.М., Никитин Н.А. Результаты интрамиокардиальной имплантации обработанных эритропоэтином аутологичных клеток костного мозга при хирургическом лечении ишемической болезни сердца с критическим поражением коронарных артерий. Рос. кардиол. ж. 2019;24(1): 62–69. doi: 10.15829/1560-4071-2019-1-62-69Fomichev A.V., Chernyavsky A.M., Gulyaeva K.K., Poveshchenko O.V., Lykov A.P., Kareva Yu.E., Minin S.M., Nikitin N.A. The results of intramiocardial implantation of autologous bone marrow cells treated with erythropoietin in surgical treatment of coronary artery disease with sever lesion of vessels. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2019;24(1):62–69. [In Russian]. doi: 10.15829/1560-4071-2019-1-62-69Lagrèze W.A., Küchlin S., Ihorst G., Grotejohann B., Beisse F., Volkmann M., Heinrich S.P., Albrecht P., Ungewiss J., Wörner M., …TONE study group. Safety and efcacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurol. 2021;20(12):991–1000. doi: 10.1016/S1474-4422(21)00322-7Lagrèze W.A., Küchlin S., Ihorst G., Grotejohann B., Beisse F., Volkmann M., Heinrich S.P., Albrecht P., Ungewiss J., Wörner M., …TONE study group. Safety and efcacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurol. 2021;20(12):991–1000. doi: 10.1016/S1474-4422(21)00322-7Juul S.E., Comstock B.A., Wadhawan R., Mayock D.E., Courtney S.E., Robinson T., Ahmad K.A., Bendel-Stenzel E., Baserga M., LaGamma E.F., … PENUT Trial Consortium. A randomized trial of erythropoietin for neuroprotection in preterm infants. N. Engl. J. Med. 2020;382(3):233–243. doi: 10.1056/NEJMoa1907423Juul S.E., Comstock B.A., Wadhawan R., Mayock D.E., Courtney S.E., Robinson T., Ahmad K.A., Bendel-Stenzel E., Baserga M., LaGamma E.F., … PENUT Trial Consortium. A randomized trial of erythropoietin for neuroprotection in preterm infants. N. Engl. J. Med. 2020;382(3):233–243. doi: 10.1056/NEJMoa1907423Wellmann S., Hagmann C.F., von Felten S., Held L., Klebermass-Schrehof K., Truttmann A.C., Knöpfli C., Fauchère J.C., Bührer C., Bucher H.U., Rüegger C.M.; Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants (EpoRepair) Investigators. Safety and short-term outcomes of high-dose erythropoietin in preterm infants with intraventricular hemorrhage: the EpoRepair randomized clinical trial. JAMA Netw. Open. 2022;5(12):e2244744. doi: 10.1001/jamanetworkopen.2022.44744Wellmann S., Hagmann C.F., von Felten S., Held L., Klebermass-Schrehof K., Truttmann A.C., Knöpfli C., Fauchère J.C., Bührer C., Bucher H.U., Rüegger C.M.; Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants (EpoRepair) Investigators. Safety and short-term outcomes of high-dose erythropoietin in preterm infants with intraventricular hemorrhage: the EpoRepair randomized clinical trial. JAMA Netw. Open. 2022;5(12):e2244744. doi: 10.1001/jamanetworkopen.2022.44744Hong J.M., Choi M.H., Park G.H., Shin H.S., Lee S.J., Lee J.S., Lim Y.C. Transdural revascularization by multiple burrhole after erythropoietin in stroke patients with cerebral hypoperfusion: a randomized controlled trial. Stroke. 2022;53(9):2739–2748. doi: 10.1161/STROKEAHA.122.038650Hong J.M., Choi M.H., Park G.H., Shin H.S., Lee S.J., Lee J.S., Lim Y.C. Transdural revascularization by multiple burrhole after erythropoietin in stroke patients with cerebral hypoperfusion: a randomized controlled trial. Stroke. 2022;53(9):2739–2748. doi: 10.1161/STROKEAHA.122.038650Minamino T., Higo S., Araki R., Hikoso S., Nakatani D., Suzuki H., Yamada T., Okutsu M., Yamamoto K., Fujio Y., … EPO-AMI-II Investigators. Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II). A randomized controlled clinical trial. Circ. J. 2018;82(4):1083–1091. doi: 10.1253/circj.CJ-17-0889Minamino T., Higo S., Araki R., Hikoso S., Nakatani D., Suzuki H., Yamada T., Okutsu M., Yamamoto K., Fujio Y., … EPO-AMI-II Investigators. Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II). A randomized controlled clinical trial. Circ. J. 2018;82(4):1083–1091. doi: 10.1253/circj.CJ-17-0889

The authors declare that there are no conflicts of interest present.